ADVATE 1500 IU

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Principio attivo:

OCTOCOG ALFA (ANTIHEMOPHILIC FACTOR RECOMBINANT)

Commercializzato da:

TAKEDA ISRAEL LTD

Codice ATC:

B02BD02

Forma farmaceutica:

POWDER FOR SOLUTION FOR INJECTION

Composizione:

OCTOCOG ALFA (ANTIHEMOPHILIC FACTOR RECOMBINANT) 1500 IU/VIAL

Via di somministrazione:

I.V

Tipo di ricetta:

Required

Prodotto da:

BAXTER AG, AUSTRIA

Gruppo terapeutico:

COAGULATION FACTOR VIII

Area terapeutica:

COAGULATION FACTOR VIII

Indicazioni terapeutiche:

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).

Data dell'autorizzazione:

2018-09-30

Scheda tecnica

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
ADVATE 250 IU powder and solvent for solution for injection.
ADVATE 500 IU powder and solvent for solution for injection.
ADVATE 1000 IU powder and solvent for solution for injection.
ADVATE 1500 IU powder and solvent for solution for injection.
ADVATE 2000 IU powder and solvent for solution for injection.
ADVATE 3000 IU powder and solvent for solution for injection.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ _
_ADVATE 250 IU powder and solvent for solution for injection. _
Each vial contains nominally 250 IU human coagulation factor VIII
(rDNA), octocog alfa. ADVATE
contains approximately 50 IU per ml of human coagulation factor VIII
(rDNA), octocog alfa after
reconstitution.
_ADVATE 500 IU powder and solvent for solution for injection. _
Each vial contains nominally 500 IU human coagulation factor VIII
(rDNA), octocog alfa. ADVATE
contains approximately 100 IU per ml of human coagulation factor VIII
(rDNA), octocog alfa after
reconstitution.
_ADVATE 1000 IU powder and solvent for solution for injection. _
Each vial contains nominally 1000 IU human coagulation factor VIII
(rDNA), octocog alfa. ADVATE
contains approximately 200 IU per ml of human coagulation factor VIII
(rDNA), octocog alfa after
reconstitution.
_ADVATE 1500 IU powder and solvent for solution for injection. _
Each vial contains nominally 1500 IU human coagulation factor VIII
(rDNA), octocog alfa. ADVATE
contains approximately 300 IU per ml of human coagulation factor VIII
(rDNA), octocog alfa after
reconstitution.
_ADVATE 2000 IU powder and solvent for solution for injection. _
Each vial contains nominally 2000 IU human coagulation factor VIII
(rDNA), octocog alfa. ADVATE
contains approximately 400 IU per ml of human coagulation factor VIII
(rDNA), octocog alfa after
reconstitution.
_ADVATE 3000 IU powder and solvent for solution for injection. _
Each vial contains nominally 3000 IU human coagulation factor VIII
(rDNA), octocog alfa. ADVATE
contains approximately 600 IU per ml